Andere talen Santhera Pharmaceuticals Holding AG

Aandelen

SANN

CH1276028821

Beurs gesloten - Swiss Exchange Andere beurzen 17:31:59 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,26 ^CHF	-1,70%		-2,83%	-5,61%

25/04	Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
25/04	Santhera Pharmaceuticals boekt weer winst in boekjaar 2023; inkomsten stijgen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Santhera dans les chiffres noirs en 2023	25/04
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	25/04
Santhera dank Catalyst-Deal mit gutem Finanzpuffer - ab 2026 Break-Even geplant	25/04
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	25/04
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	17/04
Spexis: sursis concordataire prolongé de 4 mois après réception d'un paiement	17/04
Santhera obtient un statut d'examen prioritaire en Chine pour le vamorolone	27/03
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	27/03
Santhera kommt mit möglicher Zulassung von Vamorolon in China entscheidend voran	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	27/03
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	14/03
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	14/03
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	14/03
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	21/02
Aktien Schweiz auf Erholungskurs	14/02
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	14/02
Santhera veröffentlicht Daten über Vamorolon in Fachjournal 'Neurology'	14/02
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	14/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Santhera Pharmaceuticals Holding AG

Aandelen

SANN

CH1276028821

Andere talen

Filters